Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
مقالات ISI لیگاند مرگ سلولی برنامه ریزی شده 1 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; mast cells; degranulation; Mas-related G protein-coupled receptor X2; IL-33; adhesion G protein-coupled receptor E2; tryptase; allergy; mastocytosis; ADGRE2; Adhesion G protein-coupled receptor E2; CPA3; Carboxypeptidase 3; CTMC; Connective tissue m
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; EMG; electromyographic examination; IV; intravenous; MRI; magnetic resonance imaging; NCS; nerve conduction study; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; PET; positron emission tomography;
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Unfolded protein response; Myeloid cells; T cells; Inflammation; Cell-nonautonomous; Tumor microenvironment; APC; antigen presenting cells; ATF6; activating transcription factor 6; CHOP; CCAAT/-enhancer binding protein homologous protein; DC; dendritic ce
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Melanoma; Liquid biopsy; Circulating tumor cells; Cell-free circulating tumor DNA; Cell-free DNA; Cell-free microRNA; Ab; antibody; AIM1; absent in melanoma-1; AJCC; American Joint Committee on Cancer; BRAF; B-Raf proto-oncogene, serine/threonine kinase;
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; AA; abiraterone acetate; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; AR splice variant; CRPC; castration-resistant prostate cancer; CTC; circulating tumor cell; CYP; cytochrome P450; FDA; Food and Drug Administration; LBD; ligand-bindi
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; 17-AAG; 17-(Allylamino)-17-demethoxygeldanamycin; 17-DMAG; 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; AKT; v-akt murine thymoma viral oncogene homolog; APC; antigen presenting cell; ATM; Ataxia telangiectasia mutated; ATR; Ataxia telangiectasia
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Radiation; Immunotherapy; Dose; Fractionation; MHC-I; major histocompatibility class I; ICAM-1; intercellular adhesion molecules-1; CEA; carcinoembryonic antigen; CTL; cytotoxic T cells; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; gp 100; glycopr
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; 5-ALA; 5-aminolevulinic acid; 5-FU; 5-fluorouracil; APC; antigen presenting cell; BCC; basal cell carcinoma; CAP; cold atmospheric plasma; CM; cutaneous malignant melanoma; CNP; cerium oxide nanoparticle; CNT; carbon nanotube; COX-2; cyclooxygenase II; CP
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; AE; adverse effect; APC; antigen-presenting cells; CI; confidence interval; CP; carboplatin and paclitaxel; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4; cuSCC; cutaneous squamous cell carcinoma; FDA; Food and Drug Administ
Lung abscess following bronchoscopy due to multidrug-resistant Capnocytophaga sputigena adjacent to lung cancer with high PD-L1 expression
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Lung abscess; Multidrug-resistant Capnocytophaga sputigena; Flexible bronchoscopy; Lung cancer; Programmed cell death ligand 1;
Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Programmed cell death 1; Programmed cell death ligand 1; Expression; Gastrointestinal diffuse large B cell lymphoma;
The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Pancreatic ductal adenocarcinoma; Programmed cell death ligand 1; Prognosis; Meta-analysis;
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Biomarker; Checkpoint blockade; Immunotherapy; Programmed cell death ligand 1; TNBC;
Merkel cell carcinomas infiltrated with CD33+ myeloid cells and CD8+ T cells are associated with improved outcome
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; CD33; immune infiltrate; macrophages; Merkel cell carcinoma; myeloid cells; PD-L1; AJCC; American Joint Committee on Cancer; CI; confidence interval; FFPE; formalin-fixed paraffin-embedded; HLA-DR; human leukocyte antigen-DR; HR; hazard ratio; MCC; Merk
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Small cell lung cancer; Large cell neuroendocrine lung cancer; Tumor-infiltrating immune cell; Programmed cell death ligand 1; Mutation burden;
DNA mismatch repair in cancer
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
Hypoxia and HIF pathway in cancer and the placenta
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Oxygen; Hypoxia-inducible factor; Placenta; Trophoblast; Cancer; CCRCC; clear cell renal cell carcinoma; FasL; Fas ligand; FIH; factor inhibiting HIF; FLT1; fms-related tyrosine kinase 1; HIF; hypoxia-inducible factor; HLA; human leukocyte antigen; MHC; m
Identification of repaglinide as a therapeutic drug for glioblastoma multiforme
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Repaglinide; Glioma; Bioinformatics; Drug repositioning; Cancer therapy; Brain tumor; CMap; connectivity map; DE genes; differentially expressed genes; DMEM; Dulbecco's modified Eagle's medium; DMSO; dimethyl sulfoxide; FBS; fetal bovine serum; GBM; gliob
Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; PCR; polymerase chain reaction; ECD; extracellular domain; TM; trans-membrane; CD; cytoplasmic domain; PD-L1; programmed cell death ligand 1; PDL1-ECD; programmed cell death ligand 1- extracellular domain; ERS; enzyme restriction sites; Ori; origin of rep
Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; AKT; AKT serine/threonine kinase 1; BCG; bacillus Calmette-Guérin; CTLA4; cytotoxic T-lymphocyte-associated protein 4; EGFR; epidermal growth factor receptor; FDA; Food and Drug Administration; FGFR; fibroblast growth factor receptor; GC; gemcitabine p
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: AÂ Prospective Cohort Study
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Immune checkpoint inhibitor; Immune-related adverse event; Nivolumab; Non-small cell lung cancer; Programmed cell death ligand 1;
HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Immunotoxicology; Immunotoxicity; Immunomodulation; Immunosuppression; Carcinogenicity; Cancer; Risk assessment; CTL; cytotoxic T-lymphocytes; EBV; Epstein-Barr virus; FDA; Food and Drug Administration; HESI; Health and Environmental Sciences Institute;
Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes
Keywords: لیگاند مرگ سلولی برنامه ریزی شده 1; Programmed cell death 1; Programmed cell death ligand 1; Fas; Keratinocyte; CD8 T cell; Graft-versus-host-diseaseK14-mOVA mouse, keratin 14 promoter-membrane ovalbumin-transgenic mouse; GVHD, graft-versus-host disease; DTg mouse, K14-mOVA/OT-I double tran